Drugs
-
Long-Acting Beta Agonist (LABA) Information
Long-Acting Beta Agonists (LABAs) are inhaled medications that are used in the treatment of asthma and chronic obstuctive pulmonary disease (COPD).
To report any serious adverse events associated with the use of these drugs, please contact the FDA MedWatch program using the contact information at the bottom of this page.
-
Safety Information for Consumers and Healthcare Professionals
FDA Drug Safety Communication: FDA requires post-market safety trials for Long-Acting Beta-Agonists (LABAs)
4/15/2011FDA Drug Safety Communication: Drug labels now contain updated recommendations on the appropriate use of long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs)
6/2/2010FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs)
2/18/2010Questions and Answers: New Safety Requirements for Long-Acting Asthma Medications called Long-Acting Beta Agonists (LABAs)
2/18/2010FDA Urges Safe Use of Certain Inhaled Asthma Medicines
2/18/2010Long-Acting Beta-Agonists (LABAs): New Safe Use Requirements
2/18/2010 - MedWatch- FDA Drug Info Rounds: Long-Acting Beta-Agonists (LABAs)
Training video for practicing pharmacists (7/16/2010)
-
-
Previous Safety Communications
Public Health Advisory: Update on Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder)
5/2006Information for Healthcare Professionals - Salmeterol xinafoate (marketed as Serevent Diskus)
11/2005Information for Healthcare Professionals - Fluticasone propionate; Salmeterol xinafoate (marketed as Advair Diskus)
11/2005Information for Healthcare Professionals - Formoterol fumarate (marketed as Foradil)
11/2005
-
-
-
